Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma.
AffiliationCancer Research Campaign, Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester.
MetadataShow full item record
AbstractOne hundred and fifteen patients with histologically proven primary cutaneous melanoma were entered into a randomized prospective study following surgical removal of clinically obvious regional metastases. The study started in 1977 and was completed in June 1982. Fifty-eight patients (10 with regional skin metastases and 48 with regional node metastases) were in the control group and 57 (15 regional skin, and 42 regional node metastases) received adjuvant C. parvum. Other clinical features were well balanced for each group. C. parvum, 2 mg/m2 IV was repeated eight times at three weekly intervals. The schedule was based on previous work which indicated significant increase in killer cell activity. There was no serious toxicity and 22 patients exhibited tachyphylaxis. Seventeen patients in the control group (11 tumour free) are alive at 24-80 months, and 20 patients in the C. parvum group (12 tumour free) are alive 24-76 months from randomization. No statistically significant difference (P greater than 0.05) was observed between the two patient groups for overall survival (median 26 months) or relapse free survival (median 8 months) from the date of randomization. Nor was the overall survival from the date of primary surgery (median 52 months, range 4-237) or the relapse free survival, median 28 months, range 2-225, significantly different between the two groups of patients. The relapse pattern in the two groups, and survival after relapse were no different though the response rate to actinomycin D and DTIC chemotherapy was significantly higher in the control (48 per cent) than in the C. parvum (23 per cent) group. Toxicity to chemotherapy was not significantly affected by previous C. parvum treatment. Although there were trends for better survival, in the C. parvum patient group, statistically significant activity has not been noted in this study.
CitationRandomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma. 1986, 73 (2):111-5 Br J Surg
JournalThe British Journal of Surgery
- Corynebacterium parvum followed by chemotherapy (actinomycin D and DTIC) compared with chemotherapy alone for metastatic malignant melanoma.
- Authors: Thatcher N, Wagstaff J, Mene A, Smith D, Orton C, Craig P
- Issue date: 1986 Aug
- Actinomycin-D plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamine (DTIC) with or without intravenous Corynebacterium parvum in metastatic malignant melanoma.
- Authors: Robidoux A, Gutterman JU, Bodey GP Sr, Hersh EM
- Issue date: 1982 Jun 1
- Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma.
- Authors: Lipton A, Harvey HA, Balch CM, Antle CE, Heckard R, Bartolucci AA
- Issue date: 1991 Jul
- Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma.
- Authors: Karakousis CP, Didolkar MS, Lopez R, Baffi R, Moore R, Holyoke ED
- Issue date: 1979 Nov-Dec
- DTIC and actinomycin D with and without C. parvum immunotherapy in advanced malignant melanoma.
- Authors: Halpern J, Catane R, Biran S, Fuks Z
- Issue date: 1981 May-Jun